Page last updated: 2024-10-30

memantine and Psychoses

memantine has been researched along with Psychoses in 15 studies

Research Excerpts

ExcerptRelevanceReference
"Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports."8.93Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. ( Correll, CU; Lu, RB; Luchini, C; Solmi, M; Stubbs, B; Veronese, N; Zaninotto, L, 2016)
"We sought to determine whether the extended MAPT haplotype was associated with the worsening of delusions and hallucinations in a combined cohort of 95 patients who participated in 2 clinical trials of treatment with memantine."5.19Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease. ( Ballard, C; Corbett, A; Creese, B; Fox, C; Jones, E, 2014)
"Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports."4.93Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. ( Correll, CU; Lu, RB; Luchini, C; Solmi, M; Stubbs, B; Veronese, N; Zaninotto, L, 2016)
"Although Parkinson's disease (PD) has been considered to primarily affect motor abilities, increasing emphasis is being placed on cognitive and behavioural impairment in this disorder."2.44Cognitive and behavioural impairment in Parkinson's disease. ( Freedman, M; Merims, D, 2008)
"Studies have shown that psychosis in Parkinson's disease patients is a strong risk factor for nursing home placement."2.44Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective? ( Fernandez, HH; Zahodne, LB, 2008)
"Ketamine has also been observed to exacerbate psychotic symptoms in schizophrenia patients."1.39Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Marmo, F; Sarappa, C; Tomasetti, C, 2013)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (33.33)29.6817
2010's8 (53.33)24.3611
2020's2 (13.33)2.80

Authors

AuthorsStudies
Hsu, TW1
Chu, CS1
Ching, PY1
Chen, GW1
Pan, CC1
Siao, WH1
Chang, FY1
Chen, YC1
Light, GA3
Zhang, W1
Joshi, YB1
Bhakta, S2
Talledo, JA3
Swerdlow, NR3
de Bartolomeis, A1
Sarappa, C1
Buonaguro, EF1
Marmo, F1
Eramo, A1
Tomasetti, C1
Iasevoli, F1
Creese, B1
Corbett, A1
Jones, E1
Fox, C1
Ballard, C1
Chou, HH2
Balvaneda, B2
Veronese, N1
Solmi, M1
Luchini, C1
Lu, RB1
Stubbs, B1
Zaninotto, L1
Correll, CU1
Bhakta, SG1
Rana, B1
Gaddis, L1
Merims, D1
Freedman, M1
Kyomen, HH1
Whitfield, TH1
Schmidt, R1
Baumhackl, U1
Berek, K1
Brücke, T1
Kapeller, P1
Lechner, A1
Rainer, M1
Stögerer, EM1
Osborn, GG1
Saunders, AV1
Fusar-Poli, P1
Pellegrini, F1
Cortesi, M1
Zahodne, LB1
Fernandez, HH1
Tariot, PN1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684]Phase 282 participants (Actual)Interventional2014-07-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

MATRICS Consensus Cognitive Battery Performance (MCCB)

The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionstandardized T-score (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo57.87056.000
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine54.47655.476
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo39.89538.105
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine31.89533.842

Prepulse Inhibition (PPI)

"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Intervention% inhibition of startle (Mean)
PlaceboAmphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo50.62653.029
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine50.62645.822
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo41.16239.545
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine22.62932.656

Targeted Cognitive Training (TCT): PositScience, Inc.

"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionmsec (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo-2.11329.190
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine5.91135.905
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo-50.158101.000
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine-15.11852.647

Reviews

5 reviews available for memantine and Psychoses

ArticleYear
The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: A systematic review and updated meta-analysis of double-blind randomized controlled trials.
    Journal of affective disorders, 2022, 06-01, Volume: 306

    Topics: Antidepressive Agents; Depression; Humans; Memantine; Psychotic Disorders; Randomized Controlled Tri

2022
Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions.
    Journal of affective disorders, 2016, Volume: 197

    Topics: Adult; Bipolar Disorder; Case-Control Studies; Cholinesterase Inhibitors; Clinical Trials as Topic;

2016
Cognitive and behavioural impairment in Parkinson's disease.
    International review of psychiatry (Abingdon, England), 2008, Volume: 20, Issue:4

    Topics: Antiparkinson Agents; Cognition Disorders; Dementia; Disease Progression; Humans; Incidence; Lewy Bo

2008
Current treatments for patients with Alzheimer disease.
    The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:9 Suppl 8

    Topics: Aggression; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Depression; Excitatory A

2010
Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?
    CNS spectrums, 2008, Volume: 13, Issue:3 Suppl 4

    Topics: Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; Dis

2008

Trials

4 trials available for memantine and Psychoses

ArticleYear
Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017, Volume: 42, Issue:13

    Topics: Adult; Antipsychotic Agents; Auditory Perception; Chronic Disease; Cortical Synchronization; Cross-O

2017
Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease.
    Journal of the American Medical Directors Association, 2014, Volume: 15, Issue:12

    Topics: Aged; Alleles; Alzheimer Disease; Antipsychotic Agents; Delusions; Disease Progression; Excitatory A

2014
Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy.
    Psychopharmacology, 2016, Volume: 233, Issue:12

    Topics: Adult; Biomedical Research; Cognition; Consensus; Cross-Over Studies; Double-Blind Method; Excitator

2016
[Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria].
    Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater, 2010, Volume: 24, Issue:2

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Austria; Ca

2010

Other Studies

6 other studies available for memantine and Psychoses

ArticleYear
Memantine treats psychosis and agitation associated with Moderna COVID-19 vaccine.
    Schizophrenia research, 2023, Volume: 255

    Topics: 2019-nCoV Vaccine mRNA-1273; Anxiety; COVID-19; Humans; Memantine; Psychotic Disorders

2023
Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis.
    Progress in neuro-psychopharmacology & biological psychiatry, 2013, Oct-01, Volume: 46

    Topics: Animals; Antipsychotic Agents; Carrier Proteins; Disks Large Homolog 4 Protein; Dizocilpine Maleate;

2013
Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2016, Volume: 41, Issue:2

    Topics: Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Habituatio

2016
Psychosis in the elderly.
    The American journal of psychiatry, 2009, Volume: 166, Issue:2

    Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents

2009
Memantine as a neuroprotective agent in early phases of psychosis.
    Medical hypotheses, 2007, Volume: 68, Issue:2

    Topics: Excitatory Amino Acid Antagonists; Humans; Memantine; Neuroprotective Agents; Psychotic Disorders; R

2007
Psychosis and agitation in dementia: should general psychiatrists care?
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:3

    Topics: Aged; Alzheimer Disease; Dementia; Excitatory Amino Acid Antagonists; Humans; Memantine; Psychotic D

2008